Abstract Spindle cell carcinoma (SpCC) is an uncommon head and neck squamous cell carcinoma (SCC) variant consisting of spindled and/or pleomorphic cells with epithelial differentiation. Epidermal growth factor receptor (EGFR) is expressed by [90 % of conventional SCC, and high level expression is associated with a poorer prognosis. Anti-EGFR therapies are commonly used to treat head and neck SCC. However, no studies have evaluated EGFR expression in SpCC. Cases of SpCC were retrieved from department files. The diagnosis required either a biphasic lesion with a squamous neoplastic component, or a purely spindle cell or pleomorphic tumor with immunohistochemical positivity for epithelial markers. EGFR immunohistochemistry was performed and was quantified in quartiles. Medical records were reviewed for clinical follow up information. EGFR was expressed in 21/30 (70 %) cases, including in the squamous component in 18/19 (95 %) and the spindle cell component in only 12/30 (40 %). Where the spindle cell component was positive, the intensity and distribution were lower than for the squamous component. Recurrent tumors were predominantly (80-90 %) of the spindle cell component, and had low (or absent) EGFR expression. Kaplan-Meier survival analysis showed no statistically significant differences in overall or disease free survival between the EGFR expressing and non-expressing groups (p = 0.414 and 0.19, respectively). SpCCs of the head and neck have a poor prognosis, and markedly reduced EGFR expression. EGFR-specific therapies may not be ideal for SpCC patients, which may lack EGFR expression, but further studies are needed.
Introduction
Sarcomatoid carcinoma is an unusual, histologically diverse tumor type. It is common in the head and neck as a variant of squamous cell carcinoma (SCC), and are specifically referred to as spindle cell carcinoma (SpCC) when arising there [1] [2] [3] [4] [5] . The tumors frequently present as exophytic, polypoid masses, particularly when arising in the larynx and hypopharynx, and are classically associated with a biphasic histologic appearance combining conventional SCC and spindle cell (or sarcomatoid) components [6] . A minority of cases display only the spindle cell component for which immunohistochemistry for epithelial markers such as cytokeratin and p63 are critical in differentiating them from true sarcomas and other tumors like melanoma [3, 5, 7, 8] . Molecular and ultrastructural studies have clearly shown that the spindle cell/sarcomatoid component of SpCCs is derived from the same clone as the epithelial component and thus represents divergent differentiation [3, 9, 10, 11, 12] . Although these tumors have both unique macroscopic and microscopic appearances, the demographics are very similar to conventional SCCs including the major risk factors smoking and alcohol use [1-3, 5, 13] . SpCCs do, however, occur much more frequently in sites of previous radiation therapy (as many as 15-20 % of cases) and only rarely harbor high risk human papillomavirus (HPV), regardless of the head and neck subsite involved [1-5, 7, 8, 14] . Based on a limited number of studies, early, polypoid SpCC appear to do well clinically, while higher stage tumors tend to do poorly compared to similarly staged conventional SCC [5, 13, 14] . The prognosis for SpCC patients, overall, though, appears to be similar to conventional SCCs.
While SCC is the most common malignancy in the head and neck, there is increasing recognition of the morphologic and molecular heterogeneity within it. Large numbers of studies have shown that high risk HPV, especially in the oropharynx, acts as a causative agent in SCC by suppression of the p53 and retinoblastoma proteins by the viral oncoproteins E6 and E7 [15, 16] . These HPV-related oropharyngeal SCCs also have improved prognosis when compared to their HPV negative counterparts, with HPV status clearly shown to be an independent risk factor [16, 17, 18] . In addition to HPV-related carcinogenic pathways, other drivers of development and growth for SCCs are the epidermal growth factor receptor (EGFR), transforming growth factor b (TGF-b), and phosphotidyl-inositide-3-kinase (PI3K)/AKT pathways [19] . EGFR belongs to the ERBB family of receptor tyrosine kinases signaling through the Ras-MAPK, PI3K-AKT-PTEN, and phospholipase C pathways [20] . Numerous studies have shown that not only is EGFR overexpressed in the majority of head and neck SCCs, but its overexpression is also associated with worse prognosis [21] [22] [23] [24] [25] . Based on these findings, cetuximab became the first targeted monoclonal antibody therapy against EGFR to be approved for use in head and neck SCCs. In combination with radiotherapy or cisplatinbased chemotherapy, cetuximab improves loco-regional control and overall survival [26, 27] . Several other EGFRrelated targeted agents are in development [28] .
There is abundant data on EGFR expression in conventional SCC which suggests that overexpression is prognostically adverse, although this is not a consistent finding [29] . Expression of EGFR and downstream molecules also has been suggested to predict treatment response to EGFR-targeted therapies, particularly in cell lines, but no consistent relationship between EGFR expression or mutation and treatment response for patients in routine clinical practice has been identified [30] . There is no published data on EGFR expression in head and neck SpCCs. In this study, we evaluated a series of well-characterized head and neck SpCC for EGFR expression by immunohistochemistry and correlated results with clinical and pathologic features and patient outcomes.
Materials and Methods

Study Population
This study was approved by the Human Research Protection Office of Washington University. The pathology files of Barnes-Jewish Hospital were searched from 1988 to 2009 for cases of head and neck tumors diagnosed as ''spindle cell carcinoma'', ''sarcomatoid carcinoma,'' or ''SCC with a spindle cell component.'' All biopsy and/or surgical resection specimen slides were retrieved and reviewed by two study pathologists (RFW and JSL). Representative slides from each case were subsequently independently reviewed, and the diagnosis confirmed by two other study pathologists with expertise in head and neck pathology (RDC and SEM). Cases were included only if they met the current 2005 World Health Organization definition [6] under which tumors either consist of a combination of conventional SCC and SpCC components or consist only of a spindle cell or pleomorphic, sarcomatoid tumor along a head and neck mucosal site for which there was clear demonstration of epithelial differentiation by immunohistochemistry. The latter tumors had to show positivity for at least one epithelial marker (pan-cytokeratin AE1/AE3, p63, or epithelial membrane antigen). All immunohistochemistry for epithelial differentiation was performed as part of the original workup of these tumors (i.e. no additional immunohistochemistry was performed as part of this study). In addition, pathology specimens from a recurrence or metastasis to any site which were obtained by biopsy or resection were collected and reviewed by two study pathologists (RFW and JSL) to confirm the diagnosis and determine the morphologic pattern of the recurrent/ metastatic tumor.
All clinical information including basic demographics, treatment data, clinical follow up, and survival information was obtained by review of the patients' paper and/or electronic medical records.
Immunohistochemistry
Immunohistochemistry was performed on 4 lm sections from formalin-fixed, paraffin-embedded tissue blocks using the VECTASTAIN Ò Elite ABC Kit following manufacturer's instructions using a monoclonal antibody to EGFR (Cell Signaling; clone D38B1; monoclonal; 1:100 dilution). Included in the VECTASTAIN Ò Elite ABC Kit was Head and Neck Pathol (2015) 9:360-368 361 a secondary antibody cocktail to detect binding of the primary antibody, and this complex was subsequently visualized using hydrogen peroxide substrate and a 3,3 0 -diaminodenzidine tetrahydrochloride (DAB) chromogen. Antigen retrieval was performed by boiling for 15 min in citrate buffer. Blocking was performed using normal donkey serum. EGFR cytoplasmic positivity in the basal cell layer of normal squamous epithelium on a separate positive control and also in the surrounding non-neoplastic squamous epithelium of the tumor sections was used as an internal positive control.
All primary tumors were immunostained as were the tumor specimens from recurrences and metastases, when they were biopsied or surgically resected. The distribution of staining was graded in quartiles as follows: 0 = negative, 1? = 1 to 25 % of cells positive, 2? = 26 to 50 % of cells positive, 3? = 51 to 75 % of cells positive, and 4? = 76 to 100 % of cells positive. Intensity of staining was graded subjectively in tertiles as follows: 0 = negative, 1 = weak, 2 = moderate, and 3 = intense. The antibody used does not recognize nuclear EGFR so no nuclear staining was observed. For study purposes, cases were considered EGFR positive if at least 1 % of tumor cells showed any intensity of staining. All EGFR immunostains were reviewed by two of the study pathologists (RFW and JSL), and discrepancies were resolved by consensus review.
Statistical Analysis
Statistical analyses were performed using SPSS statistics software version 20.0 (SPSS, Chicago, IL, USA) and GraphPad Prism (GraphPad Prism version 5.00 for Windows, San Diego, CA, USA). Student's t test was used in the comparison of continuous variables while Fisher's exact was used for categorical variable. Survival was estimated using the Kaplan-Meier method comparing the EGFR expressing and non-expressing tumor groups. Overall survival was defined as time from initial diagnosis to date of death, and disease-free survival was defined as time from initial diagnosis to date of first tumor recurrence or death.
Results
The basic demographic and pathologic information for the 31 identified patients is summarized in Table 1 . Overall, the demographic features were comparable to those reported in conventional SCC and other SpCC series, being predominantly Caucasian men in their 50s, 60s, or 70s with a history of smoking and/or alcohol use (over 95 % of patients). Nine (36 %) of the 25 of patients with information available had a previous history of conventional SCC of the head and neck, and 6 (24 %) had a history of prior radiation to the head and neck. The most common primary site was the oral cavity (38.7 %) followed closely by the larynx (35.5 %). Histologically, 19 (59.4 %) of the tumors were biphasic with both spindle cell and conventional SCC components, or at least with a component of squamous dysplasia (Fig. 1a, b) . The spindle cell components ranged in appearance from cases with bland, monomorphic cells in fascicles to those with highly pleomorphic morphology similar to that of undifferentiated pleomorphic sarcoma. Only one case had focal areas that resembled a defined sarcoma, in that case, an osteosarcoma. All eight monophasic tumors (spindle cell component only) were positive for at least one epithelial marker by immunohistochemistry. Six of the 8 were positive for pan-cytokeratin (AE1/AE3) or high molecular weight cytokeratin (34bE12), 3 of 8 for p63, and 1 of 8 for epithelial . In addition to the spindle cell components being less often positive for EGFR than the SCC components, the distribution and staining intensity in the spindle cell components were also lower (1.75 vs. 2.78 for distribution and 1.92 vs. 2.22 for intensity, respectively; Fig. 1c, d) .
In total, 9 out of the 31 patients had a recurrence or metastasis for which a biopsy or resection specimen was available in our pathology files and with adequate material for characterization. Histologic review of these showed that 7 of 9 (78 %) were purely spindle cell/sarcomatoid. Of the two cases that were not purely sarcomatoid, one was mixed, with the majority (70 %) being spindle cell, and the other showed only the conventional SCC component. Immunostaining for EGFR was performed and showed the SCC component of the two cases that had one to be strongly and diffusely EGFR positive. The spindle cell component was positive in all 8 of the cases that had one, but distribution and intensity were low in 5 of the 8. Specifically, most had less than 50 % of the cells positive with an intensity of 1? or 2? only. Interestingly, 6 of the 8 SpCCs for which the EGFR status could be evaluated were completely negative on the spindle cell component of the primary tumor but were then positive for EGFR on the recurrence. Clinical demographics, treatment, and outcomes for all cases by EGFR status are presented in Table 3 . Aside from the EGFR negative patients being slightly older than the EGFR positive patients (61.9 vs. 68.9 years, p = 0.036), no statistically significant differences were seen by sex, race, location of primary tumor, or stage at diagnosis between the EGFR positive and negative cases. Surgery or surgery in combination with radiation therapy was the most common primary treatment modality (78 %). The mean and median follow up times were 48.2 and 18.8 months. Overall, of the 25 patients who underwent curative intent therapy, 16 (64 %) patients suffered disease recurrence of which 13 (52 %) were local, 8 (32 %) regional, and 6 (24 %) distant. Although limited by sample size, there were minimal differences in outcomes by EGFR status, with similar rates of patients in both EGFR positive and negative groups showing regional failure (29.4 vs. 37.5 %, EGFR positive vs. negative) and distant metastases (27.8 vs. 25.0 %, EGFR positive vs. negative). There was a slightly higher rate of local recurrence in patients with EGFR positive tumors versus those that were negative (58.8 vs. 37.5 %), but small sample size precluded statistical characterization of this difference. Disease status at the end of the follow period was also similar between groups. Considering just the patients with tumors that were EGFR negative versus all other patients Kaplan-Meier survival analysis was performed comparing both groups, and this showed no significant differences in overall (p = 0.414; Fig. 2a ) or disease specific (p = 0.19; Fig. 2b ) survival, respectively. In further analysis, overall and disease specific survival between patients with EGFR positive spindle cell components were compared to patients with EGFR negative ones (ignoring the EGFR status of the conventional SCC component, if present), and again, no significant differences were seen (p = 0.18 and 0.54, respectively; Fig. 2c, d) .
We also examined the medical records for whether or not patients received EGFR inhibitor therapy. Five patients did receive cetuximab during the course of their cancer therapy and one received gefitinib. The EGFR-targeted therapy was used in two patients for primary treatment of their disease in conjunction with radiotherapy while the remaining four patients received treatment for either recurrent or metastatic disease after traditional radiation (±chemotherapy) was utilized. Interestingly, all of the patients who received EGFR-targeted therapy had tumors which were positive for EGFR in at least one component of their tumors, although this information was not known to the clinicians at the time of treatment. However, among these six patients, three had tumors with a spindle cell Table 4 . Briefly, they presented with a wide age range and sites of primary tumor. Despite EGFR-targeted therapy, four out of the six patients either had progression or only a partial response to therapy with time to progression ranging from 84 to 155 days. All four patients died with disease within 2 years of diagnosis. Of the remaining two patients, one died shortly after treatment initiation due to complications unrelated to malignancy (patient was ''censored''). However, one patient treated with EGFR-targeted therapy was alive and disease free at last follow up of almost 5 years. He had a p16 and HPV negative, strongly EGFR positive (both components), stage IVA (T1/N2b/M0) biphasic SpCC arising in the oropharynx that was treated with primary surgery with post-operative radiation and cetuximab. Time to progression for the three patients who received anti-EGFR therapies for which the tumors had a spindle cell component that was completely EGFR negative was, on average, 84 days, versus those three patients whose spindle cell component was EGFR positive, was 131 days.
Discussion
Spindle cell (sarcomatoid) carcinoma is a histologically diverse and uncommon variant of head and neck SCC with focal to extensive mesenchymal differentiation [14, 31] . They are histologically very aggressive appearing, yet prior studies on the outcome of SpCC suggest that rates of recurrence and metastases are comparable to conventional SCC, at least across all stages of disease [1, 3, 5] . The current study finds overall and disease free survival to be quite poor for SpCC patients, with only 25 % of patients alive at last follow up. EGFR is an extensively studied indicator of poor prognosis in head and neck SCCs and has been found to be expressed by tumor cells in the vast majority of cases including being markedly overexpressed in many of them [21] [22] [23] [24] [25] . Very few (\5 %) conventional SCC of the head and neck show completely absent EGFR expression [32, 33] . EGFR overexpression by immunohistochemistry or by FISH showing amplification has been associated with poorer prognosis in conventional SCC, but neither of these findings has been associated with treatment response to cetuximab [33, 34] . Activation of EGFR leads to signaling through three separate intracellular pathways including the Ras/ MAPK, PI3K/AKT, and Jak2/STAT3 pathways contributing to increased proliferation, invasion and metastasis, resistance to apoptosis, and stimulation of angiogenesis [34, 35] . These findings have led to the development and use of monoclonal antibody-directed and small molecule inhibitor therapy against EGFR in combination with conventional treatment modalities. Anti-EGFR directed therapies have been shown to improve both overall survival and Table 1 where the raw EGFR expression data are presented b Patient died of non-cancer pulmonary disease shortly after starting tyrosine kinase inhibitor therapy loco-regional control in many clinical trials for conventional SCC [26, 27] . To date, despite the importance of EGFR in tumor prognosis and treatment, there has not been a study to address the immunohistochemical expression of EGFR in SpCC. This is surprising as tumors with sarcomatoid morphology lose their epithelial characteristics so should be very likely to lose EGFR expression, especially since this has been suggested in tumors with epithelial to mesenchymal transition. In this study, we found that 30 % of SpCCs completely lacked EGFR expression. This rate is significantly more than what would be expected in conventional SCC [33] . No significant differences were found in the treatment of these patients, although six patients did receive targeted anti-EGFR therapy. Although limited by the relatively small number of patients, survival analysis showed no difference in overall survival by EGFR status (p = 0.414). Although there was trend toward possible poorer outcomes in disease-free survival in EGFR positive patients, this was not statistically significant (p = 0.19). Separate analysis of survival by just the EGFR expression of the spindle cell component alone also did not demonstrate any statistically significant differences in overall or disease-free survival, either. These findings suggest that, in contrast to conventional SCC, where levels of EGFR are prognostic, no such relationship exists for this biomarker in SpCC, although this clearly requires confirmation. Examination of the recurrences and metastases showed that they are predominantly of the spindle cell/sarcomatoid component, suggesting that it is this component that is the more aggressive. Analysis of the EGFR expression in these recurrences showed that all of these recurrences showed at least some amount of EGFR expression, although slightly less robust than the primary tumor. This shows that the recurrent tumors are not necessarily those that are completely EGFR negative, again suggesting that it is not the EGFR status that is driving the behavior and prognosis, in and of itself. The situation may simply be complicated by the fact that EGFR overexpression is generally an adverse feature, but the aggressive spindle cell component of these tumors, which we found to be the most frequent pattern in the recurrent tumors, generally has lower levels (or completely absent expression) of EGFR, such that, for prognosis, the two may ''cancel each other out''.
So even if the behavior and prognosis of SpCC is not dependent on EGFR expression, does the expression correlate with response to anti-EGFR therapies, particularly among those patients whose tumors completely lack EGFR expression? We separately assessed patients who received anti-EGFR therapy. There were three patients who had EGFR expression in both components of their cancers, and three that did not have expression in the spindle cell component. Although these are small numbers, most of these patients did poorly, similar to the remaining patients in the study. The only patient who remained alive and disease-free at last follow up had a tumor with strong EGFR expression in both tumor components. Thus, the EGFR completely negative patients did not appear to respond as well to anti-EGFR therapies in this study. Although very small numbers, this study does suggest that SpCC do not always lose all EGFR expression in the spindle cell component and thus, may still respond to anti-EGFR targeted therapies. However, our findings also raise the possibility that complete lack of EGFR expression may signify lack of response to anti-EGFR targeted therapies in SpCC patients. Further study is warranted.
In summary, SpCCs appear to be aggressive tumors frequently occurring after head and neck radiation. The majority of SpCCs express EGFR in at least one of the components, but there is a higher fraction of EGFR negative tumors than for conventional head and neck SCC. EGFR expression, when present, is generally low in the spindle cell components. EGFR expression status does not appear to be associated with patient outcomes suggesting that prognosis in these patients is largely dependent on the clinical stage and/or other factors. Analysis of the patients treated with anti-EGFR therapies demonstrated poor responses in the three patients with EGFR completely negative spindle cell components. Therefore, further evaluation of treatment response to anti-EGFR therapies in a larger number of patients with SpCC is warranted.
